.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,716,596

« Back to Dashboard

Details for Patent: 5,716,596

Title: Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
Abstract:This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to peptide derivatives and analogs of somatostatin, and embodiments of such peptides labeled with technetium-99m (Tc-99m), as well as methods and kits for making, radiolabeling and using such peptides to image sites in a mammalian body. The invention also relates to peptide derivatives and analogues of somatostatin labeled with rhemium-186 (.sup.186 Re ) and rhenium-188 (.sup.188 Re ), and methods and kits for making, radiolabeling and using such peptides therapeutically in a mammalian body.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jun 23, 1992
Application Number:07/902,935
Claims:1. A technetium-99m labeled scintigraphic imaging agent for imaging sites within a mammalian body prepared from a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR9## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L- 3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Set, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having formula:

wherein C(pgp).sup.s is a cysteine having a protected thiol group and (a) is an amino acid.

2. The technetium-99m labeled scintigraphic imaging agent of claim 1 that is a technetium-99m complex formed between a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR10## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl, substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N((R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amine acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having formula:

wherein C(pgp).sup.s is a cysteine having a protected thiol group and (aa) is an amino acid and technetium-99m in the presence of a reducing agent.

3. A technetium-99m labeled scintigraphic imagine agent that is a technetium-99m complex of claim 2 formed in the presence of a reducing agent selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

4. The technetium-99m labeled scintigraphic imaging agent of claim 1 comprising a technetium-99m complex formed between technetium-99m and a reagent that comprises, in combination, a cyclic, amine-terminally blocked somatostatin receptor binding peptide having the formula: ##STR11## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having formula;

wherein C(pgp).sup.s is a cysteine having protected thiol group and (aa) is an amino acid by ligand exchange of a pre-reduced technetium-99m complex.

5. A technetium-99m labeled scintigraphic imaging agent for imaging sites within a mammalian body prepared from a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR12## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having formula:

wherein

A is H, HOOC, H.sub.2 NOC, or --NHOC;

B is SH or NHR";

X is H, methyl, SH or NHR";

Z is H or methyl;

R and R' are independently H or lower alkyl;

R" is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and

where B is NHR", X is SH, Z is H and n is 1 or 2;

where X is NHR", B is SH, Z is H and n is 1 or 2;

here B is H, A is HOOC, H.sub.2 NOC, or --NHOC, X is SH, Z is H and n is 0 or 1;

where Z is methyl, X is methyl, A is HOOC, H.sub.2 NOC, or --NHOC, B is SH and n is 0;

and wherein the thiol moiety is in the reduced form.

6. The technetium-99m labeled scintigraphic imaging agent of claim 5 that is a technetium-99m complex formed between a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR13## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Thr or aromatic ring-substituted derivatives of D- or or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenol, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenol substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having formula:

wherein

A is H, HOOC, H.sub.2 NOC, or --NHOC;

B is SH or NHR";

X is H, methyl, SH or NHR";

Z is H or methyl;

R and R' are independently H or lower alkyl;

R" is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and

where B is NHR", X is SH, Z is H and n is 1 or 2;

where X is NHR", B is SH, Z is H and n is 0 or 1;

here B is H, A is HOOC, H.sub.2 NOC, or --NHOC, X is SH, Z is H and n is 0 or 1;

where Z is methyl, X is methyl, A is HOOC, H.sub.2 NOC, or--NHOC, B is SH and n is 0;

and wherein the thiol moiety is the reduced form, and technetium-99m in the presence of a reducing agent.

7. A technetium-99m labeled scintigraphic imaging agent that is, a technetium-99m complex of claim 6 formed in the presence of a reducing agent selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

8. The technetium-99m labeled scintigraphic imaging agent of claim 5 that is a technetium-99m complex formed between a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor for binding peptide having the formula: ##STR14## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is ether 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having formula:

wherein

A is H, HOOC, H.sub.2 NOC, or --NHOC;

B is SH or NHR";

X is H, methyl, SH or NHR";

Z is H or methyl;

R and R' are independently H or lower alkyl;

R" is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and

where B is NHR", X is SH, Z is H and n is 1 or 2;

where X is NHR", B is SH, Z is H and n is 1 or 2;

here B is H, A is HOOC, H.sub.2 NOC, or --NHOC, X is SH, Z is H and n is 0 or 1;

where Z is methyl, X is methyl, A is HOOC, H.sub.2 NOC, or --NHOC, B is SH and n is 0;

and wherein the thiol moiety is in the reduced form, and technetium-99m by ligand exchange of a pre-reduced technetium-99m complex.

9. A technetium-99m labeled scintigraphic imaging agent for imaging sites within a mammalian body prepared from a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR15## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol phenyl, phenyl, substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are, each independently H, lower linear or cyclic, alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.l is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having a formula selected from the group consisting of: ##STR16## wherein X.dbd.H or a protecting group;

(amino acid)=any amino acid; ##STR17## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

and ##STR18## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

V.dbd.H or --CO-peptide;

R'.dbd.H or peptide;

and wherein when V.dbd.H, R'=peptide and when R'.dbd.H, V.dbd.--CO-peptide;

wherein each R is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently 1 or 2;

and wherein the technetium-99m binding moiety forms an electrically-neutral complex with technetium-99m.

10. The technetium-99m labeled scintigraphic imaging agent of claim 9 that is a technetium-99m complex formed between a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR19## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2 ; where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H, or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having a formula selected from the group consisting of: ##STR20## wherein X.dbd.H or a protecting group;

(amino acid)=any amino acid; ##STR21## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

and ##STR22## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

V.dbd.H or --CO-peptide;

R'.dbd.H or peptide;

and wherein when V.dbd.H, R'=peptide and when R'.dbd.H, V.dbd.--CO-peptide;

wherein each R is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently 1 or 2;

and wherein the technetium-99m binding moiety forms an electrically-neutral complex with technetium-99m and technetium-99m in the presence of a reducing agent.

11. A technetium-99m labeled scintigraphic imaging agent that is a technetium-99m complex of claim 10 formed in the presence of a reducing agent selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

12. The technetium-99n labeled scintigraphic imaging agent of claim 9 that is a technetium-99m complex formed between a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR23## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H, lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate, or phosphate, or an amine, ether, carboxylic acid, ester, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2 ;

and a technetium-99m binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the technetium-99m binding moiety having a formula selected from the group consisting of: ##STR24## wherein X.dbd.H or a protecting group;

(amino acid)=any amino acid; ##STR25## wherein each R is independently H, CH.sub.3, or C.sub.2 H.sub.5 ;

each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

and ##STR26## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

V.dbd.H or --CO-peptide;

R'.dbd.H or peptide;

and wherein when V.dbd.H, R'=peptide and when R'.dbd.H, V.dbd.--CO-peptide;

wherein each R is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently 1 or 2;

and wherein the technetium-99m binding moiety forms an electrically-neutral complex with technetium-99m by ligand exchange of a pre-reduced technetium-99m complex.

13. A radiolabeled somatostatin receptor-binding agent that is a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR27## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D -or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H, or lower alkyl and p is either 0 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a radiolabel binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the radiolabel binding moiety having formula:

wherein C(pgp).sup.s is a cysteine having a protected thiol group and (aa) is an amino acid and that is radiolabeled with .sup.186 Re or .sup.188 Re .

14. A complex formed by reacting a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR28## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom, or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a radiolabel binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the radiolabel binding moiety having formula:

wherein C(pgp).sup.s is a cysteine having a protected thiol group and (aa) is an amino acid, with .sup.186 Re or .sup.188 Re in the presence of a reducing agent.

15. A complex according to claim 14 wherein the reagent is reacted with .sup.186 Re or .sup.188 Re in the presence of a reducing agent selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

16. A radiolabeled somatostatin receptor-binding agent that is a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR29## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys;, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a radiolabel binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the radiolabel binding moiety having formula:

wherein

A is H, HOOC, H.sub.2 NOC, or --NHOC;

B is SH or NHR";

X is H, methyl, SH or NHR";

Z is H or methyl;

R and R' are independently H or lower alkyl;

R" is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and

where B is NHR", X is SH, Z is H and n is 1 or 2;

where X is NHR", B is SH, Z is H and n is 1 or 2;

where B is H, A is HOOC, H.sub.2 NOC, or --NHOC, X is SH, Z is H and n is 0 or 1;

where Z is methyl, X is methyl, A is HOOC, H.sub.2 NOC, or --NHOC, B is SH and n is 0;

and wherein the thiol moiety is in the reduced form, and that is radiolabeled with .sup.186 Re or .sup.188 Re .

17. A complex formed by reacting a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR30## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a radiolabel binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the radiolabel binding moiety having formula:

wherein

A is H, HOOC, H.sub.2 NOC, or --NHOC;

B is SH or NHR";

X is H, methyl, SH or NHR";

Z is H or methyl;

R and R' are independently H or lower alkyl;

R" is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and

where B is NHR", X is SH, Z is H and n is 1 or 2;

where X is NHR", B is SH, Z is H and n is 1 or 2;

here B is H, A is HOOC, H.sub.2 NOC, or --NHOC, X is SH, Z is H and n is 0 or 1;

where Z is methyl, X is methyl, A is HOOC, H.sub.2 NOC, or --NHOC, B is SH and n is 0;

and wherein the thiol moiety is in the reduced form, with .sup.186 Re or .sup.188 Re in the presence of a reducing agent.

18. A radiolabeled somatostatin receptor-binding agent that is a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR31## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR.sup.9, --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a radiolabel binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the radiolabel binding moiety having a formula selected from the group consisting of: ##STR32## wherein X.dbd.H or a protecting group;

(amino acid)=any amino acid; ##STR33## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

and ##STR34## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

V.dbd.H or --CO-peptide;

R'.dbd.H or peptide;

and wherein when V.dbd.H, R'=peptide and when R'.dbd.H, V.dbd.--CO-peptide;

wherein each R is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently 1 or 2;

and that is radiolabeled with .sup.186 Re or .sup.188 Re .

19. A complex formed by reacting a reagent that comprises, in combination, a cyclic, amino-terminally blocked somatostatin receptor binding peptide having the formula: ##STR35## wherein R.sup.1 and R.sup.2 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an ether, carboxylic acid, ester or amide, or an alcohol;

R.sup.3 and R.sup.4 are each independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or where one of R.sup.3 or R.sup.4 is N(R.sup.10).sub.2, where each R.sup.10 is independently H, lower linear or cyclic alkyl or a peptide sequence of no more than 10 amino acids, and m is an integer between 0 and 3;

X.sup.1 and X.sup.2 are each independently a D- or L-amino acid, and n and q are independently either 0 or 1;

A.sup.1 is D- or L-Phe or D- or L-Tyr or aromatic ring-substituted derivatives of D- or L-Phe, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.2 is D- or L-Trp or aromatic ring-substituted derivatives of D- or L-Trp, comprising substitution of from 1 to 5 aromatic ring hydrogen atoms with a halogen atom, a sulfate, a phosphate, a nitro group, an amine, a lower linear or cyclic alkanol or a lower linear or cyclic alkyl ether;

A.sup.3 is D- or L-Lys or D- or L-N-methyl-Lys, D- or L-4-thia-Lys, D- or L-4-oxa-Lys, D- or L-4-fluoro-Lys, D- or L-5-fluoro-Lys, D- or L-3-(4-aminocyclohexyl)-Ala, or D- or L-3-(4-aminocyclohexyl)-Ala;

A.sup.4 is Thr, Ser, Val, Phe, Ile or Aib;

X.sup.3 is H, --COOR; --CH.sub.2 OH, CH.sub.2 COOR.sup.9, or --CON(R.sup.9).sub.2, where each R.sup.9 is independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or a peptide having an amino acid sequence of no more than 10 residues;

R.sup.5 and R.sup.6 are each independently H or lower alkyl and p is either 0, 1 or 2;

and

R.sup.7 and R.sup.8 are independently H, lower linear or cyclic alkyl, alkyl substituted with a halogen atom or an amine, ether or alcohol, phenyl, phenyl substituted with a halogen atom, a sulfate or phosphate, or an amine, ether, carboxylic acid, ester or amide, or an alcohol, or either R.sup.7 or R.sup.8 are --COOH, --COOR.sup.9, or --CON(R.sup.9).sub.2,

and a radiolabel binding moiety covalently linked thereto at a functional group of the peptide that does not bind to a somatostatin receptor, the radiolabel binding moiety having a formula selected from the group consisting of: ##STR36## wherein X.dbd.H or a protecting group; (amino acid)=any amino acid; ##STR37## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof; ##STR38## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

V.dbd.H or --CO-peptide;

R'.dbd.H or peptide;

and wherein when V.dbd.H, R'=peptide and when R'.dbd.H, V.dbd.--CO-peptide;

wherein each R is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy, and wherein each n is independently 1 or 2;

with .sup.186 Re or .sup.188 Re in the presence of a reducing agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc